Exelixis, Inc. (EXEL) Company Overview

What does Exelixis do?

Exelixis, Inc. is a Nasdaq-listed oncology company built economically around cabozantinib, sold in the United States as CABOMETYX tablets and COMETRIQ capsules. Exelixis discovers, develops and commercializes cancer medicines, while Ipsen and Takeda handle most international commercialization. It therefore combines a profitable franchise with a research-intensive pipeline. The official company history traces its evolution from genetics research to an integrated oncology business.

Which products and customers define the company?

CABOMETYX is the economic center. Its U.S. labels cover advanced renal cell carcinoma, previously treated hepatocellular carcinoma, refractory differentiated thyroid cancer, and previously treated pancreatic and extra-pancreatic neuroendocrine tumors. COMETRIQ treats metastatic medullary thyroid cancer but is financially small. Sales flow mainly through specialty distributors and pharmacies; demand depends on prescribing, guidelines, payer coverage, treatment duration and competing regimens.

How does Exelixis make money?

Exelixis earns U.S. net product revenue after rebates, chargebacks, government discounts and returns, plus collaboration revenue from royalties, milestones, licenses and development reimbursements. The model is less diversified than big pharma but more cash-generative than pre-commercial biotech. The latest Q1 2026 Form 10-Q shows product demand drove the latest growth.

What drives product revenue?

Q1 2026 net product revenue increased 8% year over year, driven mainly by 7% CABOMETYX unit growth and a 1% rise in average net selling price. Longer first-line renal-cell-carcinoma treatment and neuroendocrine-tumor demand supported volume. Gross product revenue of $795.4 million was reduced by $240.4 million of discounts and allowances to $555.0 million net. The 30.2% gross-to-net deduction makes payer mix and government exposure critical.

How do partnerships add leverage?

In Q1 2026, Exelixis earned $45.9 million of cabozantinib royalties from partner sales. The model therefore turns one molecule into U.S. product revenue, foreign royalties and collaborative development optionality.

What does the latest quarter show?

The first-quarter 2026 earnings release reported a stronger revenue-and-profit combination than the prior-year quarter. Total revenue rose 10% to $610.8 million, while operating expenses declined 2% to $359.5 million. This produced $251.3 million of operating income, up from $186.9 million in Q1 2025. The key signal is operating leverage: product demand rose while R&D spending temporarily declined, allowing a larger share of revenue to reach operating profit.

Why does the margin matter?

The margin is strong but not necessarily a fixed run rate. FY2026 guidance includes $875 million to $925 million of R&D and $575 million to $625 million of SG&A; launches, new trials and the gastrointestinal sales buildout can shift quarterly spending.

How concentrated is the cabozantinib franchise?

Concentration is the defining tension. FY2025 net product revenue was $2.123 billion: $2.113 billion from CABOMETYX and $9.4 million from COMETRIQ, alongside $197.3 million of collaboration revenue. Almost all product economics therefore trace to one molecule, making patent outcomes, payer access, competition and lifecycle management unusually important.

Where is revenue generated?

What protects the franchise?

The FY2025 Form 10-K lists more than 15 issued U.S. cabozantinib patents. The composition patent expires in August 2026, while patents covering forms, formulations, compositions and treatment methods extend into the early 2030s. The key question is whether those later patents withstand challenges and delay substitutable products.

Which turning points shaped Exelixis today?

Exelixis’ history is best understood as a sequence of narrowing and rebuilding. The company began with broad genetics capabilities, concentrated resources around cabozantinib, commercialized it, and then used the cash flow to rebuild a broader pipeline. Each stage changed the risk profile.

1. 1994
   Incorporated in Delaware as Exelixis Pharmaceuticals. The founding genetics platform established the discovery culture that later produced cabozantinib.
2. 2010
   Michael Morrissey became CEO after a decade at the company, providing strategic continuity through the shift toward commercialization.
3. 2016
   The FDA first approved CABOMETYX for previously treated advanced renal cell carcinoma; Exelixis also signed the Ipsen commercialization partnership.
4. 2017
   Takeda obtained Japanese commercialization rights, extending the partner-led international model.
5. 2021
   CABOMETYX plus nivolumab gained first-line advanced RCC approval, increasing duration and strategic relevance in a major tumor market.
6. 2025
   CABOMETYX gained pancreatic and extra-pancreatic neuroendocrine tumor indications, creating another growth channel beyond RCC.
7. 2026
   The FDA accepted the first zanzalintinib NDA, moving Exelixis from pipeline diversification toward a potential second commercial franchise.

What did the commercial transition change?

Commercial success created a self-funding model. FY2025 was Exelixis’ ninth consecutive operating-profit year. The company can fund pivotal trials, license assets, expand commercial infrastructure and repurchase stock without relying primarily on external financing. That freedom raises R&D’s opportunity cost: each program must compete with the established franchise’s high cash returns.

What gives Exelixis a competitive advantage?

The moat is a combination of clinical evidence, oncology commercialization, partner reach, regulatory know-how, intellectual property and internally generated funding. None is impregnable alone. Together, they make Exelixis more capable than a small biotechnology company of running broad development programs while retaining meaningful economics.

Who competes with CABOMETYX?

Competition varies by tumor and treatment line. In renal cell carcinoma, alternatives include immune-checkpoint, VEGF-targeted and HIF-2α regimens; neuroendocrine tumors also have systemic and radioligand options. Bristol Myers Squibb, Merck, Pfizer, Roche, Novartis and others bring broader portfolios, larger trial budgets and established payer relationships.

Why can the pipeline itself become a moat?

Exelixis’ official pipeline spans zanzalintinib, XL309, antibody-drug conjugates XB010 and XB371, bispecific antibody XB628 and the partnered ADU-1805 program. The advantage is not that every asset will work. It is the ability to recycle commercial cash into multiple mechanisms and modalities, while applying oncology development experience across tumor types.

Can zanzalintinib become a second franchise?

Zanzalintinib is the leading diversification option. The oral inhibitor targets TAM kinases, MET and VEGF receptors and has a roughly one-day half-life. Its first NDA, with atezolizumab for previously treated metastatic colorectal cancer, has a December 3, 2026 FDA target date. FY2026 guidance excludes potential launch revenue, so approval could add revenue but require commercial spending.

What would success change?

A successful launch would change Exelixis from a one-franchise company to a multi-franchise oncology platform. It could extend revenue duration beyond CABOMETYX’s patent and generic-entry debate, improve commercial productivity by using the same specialist infrastructure, and justify a broader terminal-growth assumption. Failure or a narrow label would leave the company more dependent on lifecycle management and earlier-stage assets.

How strong are cash flow and capital allocation?

Exelixis entered Q2 2026 with $1.426 billion of cash and marketable securities and no conventional operating debt disclosed. Q1 operating cash flow was $251.8 million; purchases of property, equipment and other assets were $1.5 million, implying a simple cash-flow-minus-capex proxy near $250.3 million. Physical capital needs are low, but clinical development and commercialization remain expensive.

How aggressive are repurchases?

By March 31, 2026, Exelixis had repurchased 13.7 million shares for $590.6 million under its October 2025 program, with $159.4 million remaining. A new $750 million authorization followed in May. Diluted shares fell from 288.2 million in Q1 2025 to 267.3 million in Q1 2026, but liquidity declined from $1.663 billion at year-end to $1.426 billion.

Who owns Exelixis, and how is it governed?

Exelixis has dispersed institutional ownership rather than founder voting control. The 2026 proxy statement reported 257.6 million shares outstanding as of February 27, 2026 for ownership calculations. Vanguard held 12.3%, BlackRock 11.1% and Farallon Capital Partners 6.1%; directors and executive officers as a group held 2.6%. Institutional concentration means governance and capital allocation can be influenced by large asset managers and active investors, but no single holder controls the vote.

What should investors know about leadership incentives?

Morrissey has been CEO since July 2010 and joined Exelixis in 2000. The board maintains audit, compensation, governance, R&D and risk committees, with key committees independent. That specialization matters for scientific, patent, pricing and capital-allocation oversight. Compensation goals link cabozantinib performance, pipeline execution and financial strength.

What risks could change the Exelixis story?

The most material risks are not generic biotechnology risks; they connect directly to the company’s concentration and reinvestment model. The same franchise that funds the pipeline is exposed to patent challenges, evolving treatment standards and payer pressure. Meanwhile, the second-franchise strategy depends on clinical and regulatory outcomes that cannot be guaranteed.

Which risk is most important?

The interaction among patent duration, CABOMETYX demand and zanzalintinib timing matters most. A favorable patent outcome gives Exelixis more time to compound cash flow and launch a successor. A successful zanzalintinib launch reduces the importance of any single CABOMETYX date. An unfavorable combination—earlier generic pressure and delayed pipeline conversion—would compress both revenue growth and the period over which high margins can be sustained.

Why does Exelixis matter for valuation?

Exelixis needs a hybrid valuation. CABOMETYX can be modeled from units, net price, gross-to-net deductions, royalties, expenses and patent-adjusted duration. Pipeline assets require separate probability-adjusted revenue, launch timing, margin and development costs. A perpetuity ignores concentration; a cash-burning-biotech frame ignores nine profitable years and substantial liquidity.

Which KPIs belong in a DCF?

The guidance range, combined with net product revenue guidance of $2.325 billion to $2.425 billion, gives analysts a near-term base. The larger valuation debate is whether those cash flows decline after cabozantinib exclusivity pressure or are replaced by zanzalintinib and the broader pipeline.

What is the key takeaway from Exelixis analysis?

Exelixis shows how one successful molecule can fund a profitable commercial platform, global partnerships and a broader research engine. FY2025 revenue was $2.320 billion, operating income $872.2 million and net income $782.6 million. Q1 2026 added 10% revenue growth, a 41.1% operating margin and $251.8 million of operating cash flow.

The strength is offset by concentration: CABOMETYX supplies almost all product revenue, so legal, competitive and reimbursement outcomes can alter cash-flow duration. The central question is whether Exelixis can establish zanzalintinib as a second franchise without sacrificing flexibility. Monitor CABOMETYX units and gross-to-net deductions, patent litigation, the December 2026 FDA decision, STELLAR readouts, spending, royalties, liquidity and repurchases.